Intercytex's ICX-PRO meets Phase IIb endpoint

Intercytex (Cambridge, U.K.) said ICX-PRO met the primary endpoint of complete wound closure at 12 weeks in a U.K. Phase IIb trial to treat venous leg ulcers. In the open-label trial, 44% of patients ...